Revive Therapeutics Ltd - RVVTF STOCK NEWS

Revive Therapeutics Ltd. (OTCQB: RVVTF) reports progress in its Phase 3 clinical trial evaluating Bucillamine for mild to moderate COVID-19. The study, in collaboration with Delta Health, targets 13 clinical sites in Turkey, aiming for full enrollment by Q2-2022. Revive plans to seek data safety monitoring board (DSMB) approval to proceed with an Emergency Use Authorization (EUA) application to the FDA. The company emphasizes the continuous need for effective treatments amidst emerging COVID-19 variants.

Revive Therapeutics Ltd. (OTCQB: RVVTF) announced that the U.S. FDA granted Orphan Drug Designation for Bucillamine to prevent ischemia–reperfusion injury (IRI) during liver transplantation. Currently, no approved treatments exist for IRI, a significant complication after liver transplants. Bucillamine could improve patient outcomes and expand the availability of quality organs for transplantation. Orphan Drug Designation provides various incentives, including seven years of exclusivity and tax credits for clinical trials, emphasizing Revive's commitment to addressing rare medical needs.

Revive Therapeutics Ltd. (OTCQB: RVVTF) has received Ethics Committee approval for its Phase 3 clinical trial in Turkey to evaluate Bucillamine, an oral treatment for mild to moderate COVID-19. The trial, conducted in partnership with Delta Health, will utilize 13 clinical sites, including major hospitals and research institutions. Turkey's ongoing battle with COVID-19, with 12.8 million infections, amplifies the urgency of this study. CEO Michael Frank emphasized this expansion supports enrollment goals and commercialization strategies for Revive's therapeutic initiatives.

Revive Therapeutics Ltd. (OTCQB: RVVTF) reported progress in its Phase 3 clinical trial for Bucillamine, targeting mild to moderate COVID-19. To date, 701 subjects have been dosed. The company is expanding enrollment into Turkey, partnering with MLP Care to leverage 30 research sites. Revive aims to complete enrollment by Q1-2022 and is preparing regulatory submissions for FDA and international approval. CEO Michael Frank emphasized the focus on finalizing enrollment and securing marketing agreements.

Revive Therapeutics Ltd. (OTCQB: RVVTF) has received IRB approval to initiate a Phase 1/2 clinical study evaluating psilocybin for methamphetamine use disorder, in collaboration with the University of Wisconsin-Madison. This study aims to gather valuable safety and efficacy data for future FDA submissions. The company is also advancing various psilocybin delivery methods, including an oral thin film strip and microneedle patch, with expected clinical studies in late 2022. Additionally, a novel biosynthetic approach for psilocybin production is underway.

Revive Therapeutics Ltd. (OTCQB: RVVTF) is advancing its Phase 3 clinical trial for Bucillamine, targeting patients with mild to moderate COVID-19. Approximately 700 subjects have enrolled, with plans to expand into Turkey by mid-February 2022. The study aims to assess Bucillamine's safety and efficacy, emphasizing that no claims are made regarding its ability to cure COVID-19. The enrollment completion is anticipated by Q1 2022. The company is leveraging FDA regulatory incentives for its drug development efforts, including Orphan Drug and Fast Track designations.

Revive Therapeutics Ltd. (OTCQB: RVVTF) reports progress in its Phase 3 clinical trial evaluating Bucillamine for treating mild to moderate COVID-19. Approximately 700 subjects have been screened, and there are no serious safety concerns reported. The company is expanding patient enrollment to Eastern Europe, particularly Turkey, to diversify its clinical population. Completion of enrollment is expected in Q1-2022, and Revive plans to file for Emergency Use Authorization with the FDA based on the trial results. CEO Michael Frank emphasized the importance of a diverse patient demographic amidst the Omicron variant.

Revive Therapeutics Ltd. (OTCQB: RVVTF) is expanding the research of Bucillamine, an oral drug with anti-viral and anti-inflammatory properties, as a treatment for the Omicron variant of COVID-19. Supported by a recent study from UCSF, Bucillamine has shown potential to inhibit SARS-CoV-2 infection, particularly the Delta variant. The company is enhancing its ongoing Phase 3 clinical study by incorporating inflammatory markers alongside viral load testing to evaluate Bucillamine's effectiveness as both an anti-viral and anti-inflammatory agent.

Revive Therapeutics Ltd. (OTCQB: RVVTF) is expanding its research on Bucillamine, an oral medication, as a potential treatment for the Omicron variant of COVID-19. Supported by a recent UCSF study, Bucillamine has shown efficacy against the Delta variant and may reduce lung injury. The ongoing Phase 3 clinical trial will now include inflammatory marker testing to evaluate Bucillamine's anti-inflammatory effects alongside its antiviral properties. CEO Michael Frank emphasized the motivation to further investigate Bucillamine's therapeutic potential in light of emerging variants.